Back to News
Market Impact: 0.2
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Source: zacks.com
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Analysts’ mean price target for Protagonist Therapeutics (PTGX) implies 25.3% upside. The article cautions that price targets have not proved reasonably effective, but says broad agreement in raising earnings estimates indicates potential upside.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
PTGX0.30
More News
- What investors need to know about Alphabet's stock-busting earnings report
- FedEx's soft holiday-quarter outlook doesn't change our view on the stock
- Breaking Down Alphabet's Disappointing Earnings Report
- The major reason Microsoft’s stock is heading higher after earnings
- We're adding a new, high-profile AI play to our Bullpen stocks to watch list
- Alphabet set to report third-quarter earnings after the bell